Benefits
Occasional heartburn comfort
In a 2-week pilot with a co-author from the earlier maker, 45 adults with heartburn after 3 to 8 meals a week were split among this fiber (2 g 30 minutes before two meals a day), a starch placebo and a comparator. On the fiber, diary-rated heartburn severity and rescue antacid use fell versus a baseline week. Placebo also had some significant effects, but the fiber's effect differed significantly from placebo. One small pilot.
Healthy blood sugar
A meta-analysis of 10 small trials found that fenugreek seed lowered fasting and post-load glucose, but significant effects appeared only at medium or high doses in people with diabetes, trials under 5 g a day showed no clear effect, and most were of low quality. They used whole seed or seed extract, not this fiber, and in a single-meal test of this fiber the glucose response did not differ from control.
Satiety and fullness
In a single-meal crossover study of this fiber, 18 adults with obesity ate breakfasts with 0, 4 or 8 g. The 8 g dose raised satiety and fullness and lowered hunger ratings over 3.5 hours. Lunch intake after 8 g was lower than after 4 g but not significantly lower than control, and intake later in the day did not differ. No body-weight trial of this ingredient is cited.
Digestive support
As a viscous soluble fiber, fenugreek galactomannan is expected to add bulk and slow the release of nutrients from a meal. These are general properties of soluble fiber; apart from the heartburn pilot, no bowel-habit, regularity or microbiome study of this ingredient is cited here.
Mechanism of action
Soluble fiber gel
Fenugreek galactomannan forms a viscous gel in water, which is expected to slow carbohydrate absorption. In the one single-meal test of this fiber, the blood glucose response did not differ from control, so this remains an expected property rather than a measured effect.
Glucose-handling support
Whole fenugreek seed also contains non-fiber constituents that have been investigated for effects on insulin signaling, largely in laboratory and animal work. Those constituents are not the galactomannan fiber, so this line describes the source plant rather than a demonstrated action of the isolated fiber fraction.
Proposed barrier effect
According to a 2011 trade report, the heartburn pilot's researchers suggested the gel-forming fiber may form a barrier against stomach acid. This was not measured in the trial and remains a hypothesis.
Clinical trials
Meta-analysis of 10 clinical trials (278 participants) of fenugreek seed preparations lasting at least 1 week. (Neelakantan et al. 2014, Nutrition Journal)
Mostly adults with type 2 diabetes; one trial in type 1 diabetes and two in adults without diabetes. Doses ranged from 1 g to 100 g of seed a day (median 25 g), given as seed powder, debitterized seed powder or a hydro-alcoholic seed extract.
Versus control, fenugreek lowered fasting glucose by 0.96 mmol/l (10 trials), 2-hour post-load glucose by 2.19 mmol/l (7 trials) and HbA1c by 0.85% (3 trials). Heterogeneity was high for the glucose measures. Significant fasting and 2-hour effects were found only for medium or high doses in people with diabetes, and most trials were of low methodological quality. None tested an isolated galactomannan fiber, so this is class evidence for fenugreek, not a FenuLife® trial.
Pilot study with starch placebo and ranitidine arms, 2 weeks; a trade report says participants were randomly assigned and calls it a Frutarom study, and one co-author was from Frutarom. (DiSilvestro et al. 2011, Phytotherapy Research)
45 adults aged 32 to 62 (21 non-smoking men, 24 non-pregnant women) with heartburn after 3 to 8 meals a week for at least a month, not taking prescription heartburn drugs. The abstract does not name the product; trade reports identify it as FenuLife®.
Taken as 2 g (four 500 mg capsules) 30 minutes before two meals a day, the fiber lowered diary-rated heartburn severity and rescue antacid use versus a baseline week. The starch placebo also produced some significant effects, but the fiber's effects differed significantly from placebo. A third arm took ranitidine 75 mg twice daily as an active comparator. Small and short, with a co-author from the maker.
Single-blind randomized crossover study of three test breakfasts; a 2009 trade report says it was funded by the NIH and Frutarom USA. (Mathern et al. 2009, Phytotherapy Research)
18 healthy adults with obesity. The abstract does not name the product; a 2009 trade report identifies it as FenuLife®.
Breakfasts with 0, 4 or 8 g of isolated fenugreek fiber were compared over 3.5 hours. The 8 g dose significantly raised satiety and fullness ratings and lowered hunger and prospective food consumption. Glucose AUC did not differ among treatments, and insulin AUC rose with 8 g. Lunch intake was lower after 8 g than 4 g but not significantly lower than control (p = 0.11), and later intake did not differ. Palatability fell as the dose rose.